Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Philogen SpA ( (IT:PHIL) ) just unveiled an update.
Philogen S.p.A. announced an update on its share buyback program, revealing the purchase of 6,473 shares between March 24 and March 28, 2025, at an average price of Euro 19.4810 per share, totaling Euro 126,100.61. This move is part of a broader strategy to manage capital structure, with the company having acquired a total of 41,457 shares since the program’s inception. The buyback program reflects Philogen’s confidence in its market positioning and aims to enhance shareholder value.
More about Philogen SpA
Philogen is an Italian-Swiss biotechnology company specializing in the research and development of pharmaceutical products for high-mortality diseases. The company focuses on discovering and developing targeted anti-cancer drugs using high-affinity ligands for tumor markers. Their main therapeutic strategy involves tumor targeting, which selectively delivers potent therapeutic agents to tumors while sparing healthy tissues. Philogen aims to generate innovative treatments for diseases lacking satisfactory therapies, leveraging proprietary technologies, development experience, and a broad portfolio of patents.
YTD Price Performance: -0.53%
Average Trading Volume: 290
Technical Sentiment Signal: Sell
Current Market Cap: €573.2M
For an in-depth examination of PHIL stock, go to TipRanks’ Stock Analysis page.